BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company s Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs
News provided by
Share this article
Share this article
SUNNYVALE, Calif., May 5, 2021 /PRNewswire/ BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, announced today it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture.
BridGene plans to use proceeds from the Series A financing to expand the company s proprietary covalent library to discover small-molecule ligands for a broader range of targets, advance existing oncology programs and enhance operations.
Published: May 05, 2021 By Mark Terry
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
Esker Launches with $70 Million Series A
San Francisco-based Esker Therapeutics, a Foresite Labs-incubated company,
launched with a $70 million Series A financing. The round was led by Foresite Capital. The company focuses on autoimmune diseases and so-called precision therapies that target patients most likely to benefit from them.
The company’s precision analytics platform is powered by Foresite Labs. The technology platform is made up of high-quality curated genetic, clinical and medical record data, a systems immunology approach for prospective data collections and tools for building patient registries. Its lead pipeline product is ESK-001, a highly selective TYK2 inhibitor with greater selectivity for TYK2 over JAK1, initially in development for psoriasis. It is currently in a Phase
China Digest: GL Ventures backs Sobot; Daoer to raise $75m; Xiaohongshu mulls US IPO
Source: Andy Kelly/Unsplash
April 28, 2021
Chinese cloud-based intelligent customer service startup Sobot Technologies and Daoer Biologics have raised funds, while Xiaohongshu is reportedly mulling an IPO.
GL Ventures leads $31m Series C+ round for Sobot
GL Ventures, the venture capital (VC) arm of investment firm Hillhouse Capital, has led a 200 million yuan ($30.8 million) Series C+ round of financing for Chinese cloud-based intelligent customer service startup Sobot Technologies, alongside capital injection from China-focused VC Yunqi Partners.
Beijing-based Sobot leverages AI and big data to help clients integrate and manage their call centres, chatbots, manual customer services, and work order systems. The startup has forged partnerships with over 300,000 corporates across the fields of consumer & retail, education, corporate services, gaming, and public service as of April 2021.
Reddit and 20 other Bay Area companies rake in $1 billion at midweek - Silicon Valley Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Teon Therapeutics Completes $30 Million Series A Financing
News provided by
Share this article
Share this article
SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways, today announced the completion of a $30M Series A financing. The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments, and former Gilead senior executives. All existing investors also participated in the financing round including Northern Light Venture Capital, Kaitai Capital and Oriental Fortune Capital. The funds will be used to advance the company s lead A